NeoGenomics, Inc. (NEO) vs Sotera Health Company (SHC)
NeoGenomics, Inc. and Sotera Health Company are both Diagnostics & Research companies. Sotera Health Company is the larger, with a market value of $5.3B against $2.5B — 2.1× the size. NeoGenomics, Inc. has negative trailing earnings, so its P/E is not meaningful; Sotera Health Company trades at 32.1×. NeoGenomics, Inc. grew revenue faster over the last twelve months: 11.2% against 8.15%. Sotera Health Company has the higher net margin (13.4% vs −6.77%) and the higher return on invested capital (9.82% vs −4.20%). Across the 18 metrics below, Sotera Health Company leads on 10 and NeoGenomics, Inc. on 8.
Valuation
Profitability
| Metric | NEO | SHC | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 43.92% | 54.97% | 50.89% |
| Operating margin | (8.93%) | 32.82% | (8.57%) |
| Net margin | (6.77%) | 13.44% | (6.37%) |
| Free cash flow margin | (0.69%) | 9.27% | 0.00% |
| Return on equity | (6.33%) | 27.78% | (2.92%) |
| Return on assets | (3.78%) | 5.01% | (6.71%) |
| Return on invested capital | (4.20%) | 9.82% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack